<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354393</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000486304</org_study_id>
    <secondary_id>CASE-CCF-IRB-5179</secondary_id>
    <secondary_id>CASE-CCF-0755</secondary_id>
    <nct_id>NCT00354393</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma</brief_title>
  <official_title>Aggressive Multi-Modality Management of Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as methotrexate, vinorelbine, and cisplatin, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller&#xD;
      and reduce the amount of normal tissue that needs to be removed. Radiation therapy uses&#xD;
      high-energy x-rays to kill tumor cells. Cisplatin may also make tumor cells more sensitive to&#xD;
      radiation therapy. Giving chemotherapy and radiation therapy after surgery may kill any tumor&#xD;
      cells that remain after surgery.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving combination chemotherapy with or&#xD;
      without surgery and chemoradiotherapy works in treating patients with malignant pleural&#xD;
      mesothelioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Assess the response to induction combination chemotherapy comprising methotrexate,&#xD;
           vinorelbine ditartrate, and cisplatin in patients with previously untreated malignant&#xD;
           pleural mesothelioma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Assess the tolerability and toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine relapse-free and overall survival of patients treated with induction&#xD;
           combination chemotherapy with or without surgery and hemithoracic radiation.&#xD;
&#xD;
        -  Assess the impact of induction combination chemotherapy on operability and surgical&#xD;
           success.&#xD;
&#xD;
        -  Evaluate the impact of these treatment regimens on quality of life.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Induction chemotherapy: Patients receive MVP chemotherapy comprising cisplatin IV over&#xD;
           30-60 minutes on day 1 and vinorelbine ditartrate IV over 5-10 minutes and methotrexate&#xD;
           IV over 5-30 minutes on days 8, 15, and 22. Treatment repeats every 28 days for 2&#xD;
           courses. Patients with unresectable disease may receive up to 2 additional courses of&#xD;
           induction chemotherapy. Patients requiring palliative radiotherapy or who have&#xD;
           progressive disease are removed from the study. Patients with resectable disease or&#xD;
           sarcomatoid histology and T1-3, N1-2 disease with a complete or partial response to&#xD;
           induction chemotherapy proceed to surgery.&#xD;
&#xD;
        -  Surgery: Patients with extensive disease undergo palliative debulking pleurectomy and&#xD;
           decortication and then are taken off study. All other patients undergo a thoracotomy&#xD;
           with an extrapleural pneumonectomy and then proceed to chemoradiotherapy.&#xD;
&#xD;
        -  Chemoradiotherapy: Beginning 6-10 weeks after surgery, patients undergo 3-dimensional&#xD;
           conformal or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks.&#xD;
           Patients also receive cisplatin IV over 30-60 minutes on days 1 and 22. Patients with&#xD;
           responding disease proceed to adjuvant chemotherapy.&#xD;
&#xD;
        -  Adjuvant chemotherapy: Patients receive 2 additional courses of MVP chemotherapy as&#xD;
           above.&#xD;
&#xD;
      Quality of life is assessed at baseline, after each course of induction chemotherapy, before&#xD;
      surgery, and then every 3 months thereafter.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to chemotherapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability and toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free and overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operability and surgical success</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Malignant Mesothelioma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine ditartrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-dimensional conformal radiation therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant pleural mesothelioma&#xD;
&#xD;
               -  Amenable to aggressive surgical resection, if deemed resectable&#xD;
&#xD;
                    -  Patients with potentially resectable disease must have undergone&#xD;
                       mediastinoscopy to establish surgical stage&#xD;
&#xD;
                         -  Resectable disease is defined as any of the following:&#xD;
&#xD;
                              -  Epithelioid, mixed histology, or histology not otherwise specified&#xD;
                                 with clinical stage I-III (T1-3, N0-2, M0) disease&#xD;
&#xD;
                              -  Sarcomatoid histology with clinical stage I-III (T1-3, N0) disease&#xD;
&#xD;
               -  Intraperitoneal extension, contralateral thoracic extension, or distant&#xD;
                  metastases are eligible, but considered unresectable&#xD;
&#xD;
                    -  Disease considered unresectable by any medical reason or if surgery was&#xD;
                       declined&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  WBC ≥ 3,000/mm³&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm³&#xD;
&#xD;
          -  Creatinine ≤ 1.7 mg/dL&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2 times normal&#xD;
&#xD;
          -  AST &lt; 2 times normal&#xD;
&#xD;
          -  Albumin &gt; 3 g/dL&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Patients must be available for and compliant with adequate long-term follow-up&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Patients with resectable disease must have adequate pulmonary function to undergo&#xD;
             surgery and radiotherapy&#xD;
&#xD;
          -  No other active malignancies&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior surgical resection, radiation therapy, chemotherapy, or immunotherapy for&#xD;
             this cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J. Adelstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>July 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <keyword>localized malignant mesothelioma</keyword>
  <keyword>sarcomatous mesothelioma</keyword>
  <keyword>advanced malignant mesothelioma</keyword>
  <keyword>epithelial mesothelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

